3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hematologic Diseases
1
Endometrial Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bone Marrow Diseases
1
Abiraterone Acetate
1
Interventions
Imatinib Mesylate
10
Peripheral Blood Stem Cell Transplantation
8
Hydroxyurea
7
Interferon-alpha
6
Cytarabine
6
Radiotherapy
4
Filgrastim
4
Dasatinib
4
Cyclosporine
4
Cyclophosphamide
4
Busulfan
4
nilotinib
3
Methotrexate
3
Idarubicin
3
Early Intervention, Educational
3
olverembatinib
2
liposomal amphotericin B
2
Therapeutics
2
Psychiatric Rehabilitation
2
Mycophenolic Acid
2
Etoposide
2
Cyclosporins
2
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2
sargramostim
1
ponatinib
1
peginterferon alfa-2b
1
fludarabine phosphate
1
bosutinib
1
asciminib
1
Whole-Body Irradiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myeloid, Chronic-Phase
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts